COCP Cocrystal Pharma Inc
Price (delayed)
$1.701
Market cap
$17.31M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.85
Enterprise value
$6.06M
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), hepatitis C viruses and noroviruses.
Highlights
Cocrystal Pharma's EPS has increased by 8% YoY but it has decreased by 4.5% from the previous quarter
The company's equity has shrunk by 59% YoY and by 27% QoQ
The company's quick ratio has shrunk by 57% YoY and by 2% QoQ
Key stats
What are the main financial stats of COCP
Market
Valuations
Earnings
Shares outstanding
10.17M
Market cap
$17.31M
Enterprise value
$6.06M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.36
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$19.31M
Net income
-$18.7M
EBIT
-$18.19M
EBITDA
-$18.22M
Free cash flow
-$16.72M
Per share
Balance sheet
Liquidity
EPS
-$1.85
EPS diluted
-$1.85
Free cash flow per share
-$1.64
Book value per share
$1.25
Revenue per share
$0
TBVPS
$1.6
Total assets
$16.23M
Total liabilities
$3.53M
Debt
$1.88M
Equity
$12.7M
Working capital
$12.31M
Debt to equity
0.15
Current ratio
7.32
Quick ratio
6.74
Net debt/EBITDA
0.62
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-78.2%
Return on equity
-94.6%
Return on invested capital
-564.5%
Return on capital employed
-127.3%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
COCP stock price
How has the Cocrystal Pharma stock price performed over time
Intraday
-3.35%
1 week
-1.68%
1 month
-7.05%
1 year
15.71%
YTD
-15.79%
QTD
-15.79%
Financial performance
How have Cocrystal Pharma's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$19.31M
Net income
-$18.7M
Gross margin
N/A
Net margin
N/A
The operating income has contracted by 5% YoY and by 3.2% from the previous quarter
Cocrystal Pharma's net income has decreased by 4.3% from the previous quarter and by 3.8% YoY
Growth
What is Cocrystal Pharma's growth rate over time
Valuation
What is Cocrystal Pharma stock price valuation
P/E
N/A
P/B
1.36
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Cocrystal Pharma's EPS has increased by 8% YoY but it has decreased by 4.5% from the previous quarter
The company's equity has shrunk by 59% YoY and by 27% QoQ
The stock's P/B is 36% above its 5-year quarterly average of 1.0 and 36% above its last 4 quarters average of 1.0
Efficiency
How efficient is Cocrystal Pharma business performance
Cocrystal Pharma's ROE has plunged by 83% YoY and by 28% from the previous quarter
The ROA has plunged by 60% YoY and by 22% from the previous quarter
COCP's return on invested capital is up by 46% year-on-year and by 11% since the previous quarter
Dividends
What is COCP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for COCP.
Financial health
How did Cocrystal Pharma financials performed over time
The company's total liabilities has surged by 83% YoY but it fell by 16% QoQ
The company's quick ratio has shrunk by 57% YoY and by 2% QoQ
The debt is 85% less than the equity
The company's equity has shrunk by 59% YoY and by 27% QoQ
COCP's debt to equity has soared by 50% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.